PF‐04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo‐Controlled Study

This phase Ib study randomized patients with stable sickle cell disease (SCD) aged 18–65 years to twice‐daily PF‐04447943 (a phosphodiesterase 9A inhibitor; 5 or 25 mg) or placebo, with/without hydroxyurea coadministration, for up to 29 days. Blood samples were collected at baseline and various post...

Descripción completa

Detalles Bibliográficos
Autores principales: Charnigo, Robert J., Beidler, David, Rybin, Denis, Pittman, Debra D., Tan, Beesan, Howard, Jo, Michelson, Alan D., Frelinger, Andrew L., Clarke, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440678/
https://www.ncbi.nlm.nih.gov/pubmed/30597771
http://dx.doi.org/10.1111/cts.12604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440678/
https://www.ncbi.nlm.nih.gov/pubmed/30597771
http://dx.doi.org/10.1111/cts.12604

Ejemplares similares